In recent years, two major classes of epigenetic drugs, histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, have demonstrated significant potential as immunomodulatory agents in diseases such as cancer [67–69]. Here, DNMT1 is linked to cancer.